Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2019 16:15 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
August 22, 2019 08:45 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization...
August 13, 2019 16:05 ET | Source: Protalix BioTherapeutics, Inc.

Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics

CARMIEL, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Shlomo Yanai has resigned from the Company’s Board of Directors...
August 08, 2019 06:05 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update

CARMIEL, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
July 29, 2019 16:01 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019

CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
July 29, 2019 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer

CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Eyal Rubin has been appointed to serve as the Company’s new...
June 17, 2019 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease

CARMIEL, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
June 06, 2019 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

CARMIEL, Israel, June 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), or Protalix, and Chiesi Farmaceutici S.p.A, an international research-focused...
May 21, 2019 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director

CARMIEL, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Dror Bashan has been appointed to serve as the Company’s new...
May 06, 2019 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update

CARMIEL, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...

Next Page keyboard_arrow_right